• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BIMI International Medical Inc. (Amendment)

    3/3/22 2:27:34 PM ET
    $BIMI
    Other Pharmaceuticals
    Health Care
    Get the next $BIMI alert in real time by email
    SC 13G/A 1 bimi_13ga.htm BIMI 13GA

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    BIMI International Medical Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    05552Q202

    (CUSIP Number)
     

    December 31, 2021**

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    **This Schedule 13G/A amends and restates the Schedule 13G/A filed by the Reporting Person on February 2, 2022 ("Amendment No. 1"), as Amendment No. 1 did not take into account the 4.99% Blocker (as defined in Item 4).

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     

     

    1

    NAME OF REPORTING PERSON

    Hudson Bay Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,920,509 shares of Common Stock issuable upon exercise of warrants and/or conversion of convertible notes* (see Item 4)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,920,509 shares of Common Stock issuable upon exercise of warrants and/or conversion of convertible notes* (see Item 4)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,920,509 shares of Common Stock issuable upon exercise of warrants and/or conversion of convertible notes* (see Item 4)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.99%* (see Item 4)

    12

    TYPE OF REPORTING PERSON

    PN

             

     

    * As more fully described in Item 4, these shares of Common Stock are issuable upon exercise of warrants and/or conversion of convertible notes, which are each subject to a 4.99% beneficial ownership blocker and the percentage set forth on row (11) and the number of shares of Common Stock set forth on rows (6), (8) and (9) give effect to such blocker.

     
     

     

    1

    NAME OF REPORTING PERSON

    Sander Gerber

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,920,509 shares of Common Stock issuable upon exercise of warrants and/or conversion of convertible notes* (see Item 4)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,920,509 shares of Common Stock issuable upon exercise of warrants and/or conversion of convertible notes* (see Item 4)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,920,509 shares of Common Stock issuable upon exercise of warrants and/or conversion of convertible notes* (see Item 4)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.99%* (see Item 4)

    12

    TYPE OF REPORTING PERSON

    IN

             

     

    * As more fully described in Item 4, these shares of Common Stock are issuable upon exercise of warrants and/or conversion of convertible notes, which are each subject to a 4.99% beneficial ownership blocker and the percentage set forth on row (11) and the number of shares of Common Stock set forth on rows (6), (8) and (9) give effect to such blocker.

     
     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is BIMI International Medical Inc., a Delaware corporation (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 9th Floor, Building 2, Chongqing Corporation Avenue, Yuzhong District, Chongqing, P. R. China, 116000.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by Hudson Bay Capital Management LP (the "Investment Manager") and Mr. Sander Gerber ("Mr. Gerber"), who are collectively referred to herein as "Reporting Persons."

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 28 Havemeyer Place, 2nd Floor, Greenwich, Connecticut 06830.

     

    Item 2(c). CITIZENSHIP:
       
      The Investment Manager is a Delaware limited partnership.  Mr. Gerber is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      05552Q202

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ý Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) ý

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

     
     

     

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      This Schedule 13G/A amends and restates Amendment No. 1, as Amendment No. 1 did not take into account the 4.99% Blocker.
       
      The percentages used in this Schedule 13G are calculated based upon 36,566,651 shares of Common Stock outstanding as of November 15, 2020, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 filed with the Securities and Exchange Commission on November 15, 2021 and assume the exercise of warrants and the conversion of convertible notes held by, and the conversion of convertible notes issuable upon the exercise of rights held by, Hudson Bay Master Fund Ltd. (collectively, the "Securities"), subject to the 4.99% Blocker (as defined below).  
       
      Pursuant to the terms of the Securities, the Reporting Persons cannot exercise or convert such Securities if the Reporting Persons would beneficially own, after such exercise or conversion, more than 4.99% of the outstanding shares of Common Stock (the "4.99% Blocker").  The percentage set forth on Row (11) and the number of shares of Common Stock set forth on rows (6), (8) and (9) of the cover page for each Reporting Person give effect to the 4.99% Blocker. Consequently, at this time, the Reporting Persons are not able to exercise or convert all of the Securities due to the 4.99% Blocker.
       
      The Investment Manager serves as the investment manager to Hudson Bay Master Fund Ltd., in whose name the reported shares of Common Stock are held. As such, the Investment Manager may be deemed to be the beneficial owner of all shares of Common Stock, subject to the 4.99% Blocker, underlying the Securities held by Hudson Bay Master Fund Ltd.  Mr. Gerber serves as the managing member of Hudson Bay Capital GP LLC, which is the general partner of the Investment Manager.  Mr. Gerber disclaims beneficial ownership of these securities.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
     
     

     

      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ý

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 4.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURES

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: March 3, 2022

     

    HUDSON BAY CAPITAL MANAGEMENT LP    
         
         
    By: /s/ Sander Gerber    
    Name: Sander Gerber    
    Title: Authorized Signatory    
         
         
    /s/ Sander Gerber    
    SANDER GERBER    

     

    Get the next $BIMI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIMI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIMI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BIMI Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq

      New York, May 20, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as BIMI International Medical Inc., a healthcare products and services provider, today announced that on May 17, 2024, it received a delinquency compliance alert notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that due to its failure to timely file its Form 10-Q for the period ended March 31, 2024, with the Securities and Exchange Commission (the "SEC"), and because the Company remains delinquent in filing its Form 10-K for the fiscal year ended December 31, 2023, it is not in compliance with Nasdaq's contin

      5/20/24 4:09:46 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq

      New York, April 23, 2024 (GLOBE NEWSWIRE) --  BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as BIMI International Medical Inc., a healthcare products and services provider, today announced that on April 19, 2024, it received a delinquency compliance alert notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (

      4/23/24 4:05:00 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI Announces Results of 2023 Annual General Meeting of Stockholders

      New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as (BIMI International Medical Inc.) a healthcare products and services provider, today announced the results of the Company's 2022 Annual General Meeting of Stockholders (the "Annual Meeting") held on Dec 29, 2023 at 11:00 a.m. at the offices of the Company, 725 5th Ave, New York, NY 10022. At the Annual General Meeting the shareholders voted and approved; 1. The election of seven directors to serve on the board of directors of the Company, until the next annual meeting of Stockholders and until their respective successors have been duly elected and quali

      1/3/24 7:00:00 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care

    $BIMI
    Financials

    Live finance-specific insights

    See more
    • BIMI International Medical Inc. Announces Third Quarter 2023 Financial Results

      NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) --  BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months and nine months ended September 30, 2023. Revenues for the three months ended September 30, 2023 and 2022 were $2,523,193 and $4,932,479, respectively. Revenues for the nine months ended September 30, 2023 and 2022 were $11,278,496 and $10,476,224, respectively. The revenues of the Zhongshan, Qiangsheng, Eurasia, and Minkang hospitals, that are held for sale, were accounted for separately. Net loss for the three months ended September 30, 2023 and 2022 was $3,134,072 and $3,099,662, respectively, whi

      12/19/23 8:01:00 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI International Medical Inc. Announces Second Quarter 2023 Financial Results

      NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months ended June 30, 2023. The Company reported a significant increase in gross margin underlining the ongoing success of its business strategy and operational effectiveness. Revenues for the six months ended June 30, 2023 and 2022 were $8,755,303 and $5,543,745, respectively. Compared with the same period in 2022, revenue increased by $3,211,558, due to the inclusion of the revenues of Phenix Bio Inc., which was acquired on March 15, 2023. The revenues of the Zhongshan, Qiangsheng, Eurasia, and Minkang h

      11/27/23 8:25:00 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI International Medical Inc. Announces First Quarter 2023 Financial Results

      NEW YORK, May 22, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (the "Company"), a leading medical solutions provider, today announced its financial results for the three months ended March 31, 2023. The Company reported a significant decrease in net losses and notable improvements in working capital, underlining the ongoing success of its business strategy and operational effectiveness. Revenues for the three months ended March 31, 2023 and 2022 were $3,197,637 and $2,714,711, respectively. The revenues for the three months ended March 31, 2023 were primarily attributable to the revenues from sales of healthcare products by Phenix Bio Inc., a newly acquired subsidiary, and  fr

      5/22/23 9:25:53 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care

    $BIMI
    SEC Filings

    See more
    • BIMI International Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BIMI Holdings Inc. (0001213660) (Filer)

      7/29/24 4:01:18 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI International Medical Inc. filed SEC Form 8-K: Leadership Update

      8-K - BIMI Holdings Inc. (0001213660) (Filer)

      6/4/24 4:30:41 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI International Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - BIMI Holdings Inc. (0001213660) (Filer)

      5/24/24 4:01:39 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care

    $BIMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Oudom Fnu was granted 1,123,500 shares, increasing direct ownership by 285% to 1,518,243 units (SEC Form 4)

      4 - BIMI Holdings Inc. (0001213660) (Issuer)

      6/13/24 1:06:18 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • New insider Smith Symington Wei claimed ownership of 3,456 shares (SEC Form 3)

      3 - BIMI Holdings Inc. (0001213660) (Issuer)

      3/20/24 8:04:41 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • Tiewei Song sold $2,903 worth of shares (724 units at $4.01), decreasing direct ownership by 0.21% to 341,117 units (SEC Form 4)

      4 - BIMI Holdings Inc. (0001213660) (Issuer)

      3/4/24 4:03:12 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care

    $BIMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by BIMI International Medical Inc. (Amendment)

      SC 13D/A - BIMI Holdings Inc. (0001213660) (Subject)

      1/11/24 4:46:28 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by BIMI International Medical Inc. (Amendment)

      SC 13D/A - BIMI International Medical Inc. (0001213660) (Subject)

      12/19/23 4:01:04 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D filed by BIMI International Medical Inc.

      SC 13D - BIMI International Medical Inc. (0001213660) (Subject)

      8/8/22 4:45:19 PM ET
      $BIMI
      Other Pharmaceuticals
      Health Care

    $BIMI
    Leadership Updates

    Live Leadership Updates

    See more
    • BIMI Announces Results of 2023 Annual General Meeting of Stockholders

      New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- BIMI Holdings Inc. (NASDAQ:BIMI) ("BIMI" or the "Company"), previously known as (BIMI International Medical Inc.) a healthcare products and services provider, today announced the results of the Company's 2022 Annual General Meeting of Stockholders (the "Annual Meeting") held on Dec 29, 2023 at 11:00 a.m. at the offices of the Company, 725 5th Ave, New York, NY 10022. At the Annual General Meeting the shareholders voted and approved; 1. The election of seven directors to serve on the board of directors of the Company, until the next annual meeting of Stockholders and until their respective successors have been duly elected and quali

      1/3/24 7:00:00 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc's Appointment of Hong Kong, Taiwan, and Macau Exclusive Distributor

      NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI, "BIMI"))), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company ("Hao Mu"), as its exclusive distributor responsible for the distribution of Phenix's 17 herbal supplements in Hong Kong, Taiwan and Macau. Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases of at least $5 million in order to maintain its exclusive distributor status for this territory. Under the terms of this agreement, Phenix's comprehensive portfolio of high-quality herbal su

      10/30/23 9:29:00 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care
    • BIMI International Medical Inc. Announces Subsidiary Phenix Bio Inc's Appointment of Mainland China Non-Exclusive Distributor

      NEW YORK, NY, Oct. 30, 2023 (GLOBE NEWSWIRE) -- BIMI International Medical Inc. (NASDAQ:BIMI, "BIMI"))), a healthcare products and services provider today announced that its subsidiary, Phenix Bio Inc., appointed Hao Mu Pte. Ltd., a Singapore company ("Hao Mu"), as a distributor responsible for the distribution of Phenix's 17 herbal supplements in Mainland China. Pursuant to the terms of a sales agreement entered into on October 29, 2023, Hao Mu must make annual purchases of at least $5 million in order to maintain its distributor status for this territory. Under the terms of this agreement, Phenix's comprehensive portfolio of high-quality herbal supplements will be made available to co

      10/30/23 9:27:00 AM ET
      $BIMI
      Other Pharmaceuticals
      Health Care